Table 1.
Patient characteristics.
| Total enrolled patients, n (%) | 104 |
| Cycle 1 | 104 (100.0) |
| Cycle 4 | 75 (72.1) |
| Cycles of bortezomib treatment, mean ± SD | 4.6 ± 2.2 |
| Sex, n, M/F (%) | 56/48 (53.9/46.1) |
| Age at treatment, n, <65/≥65 (%) | 67/37 (64.4/35.6) |
| ECOG performance status, n (%) | |
| 0 | 23 (22.1) |
| 1 | 56 (53.9) |
| 2 | 23 (22.1) |
| 3 | 2 (1.9) |
| 4 | 0 |
| Quantity of M-protein (g/L) in SPEP, median (range) | 1.3 (0.0–6.7) |
| Hb ≤ 10.0 g/dL, n/median (%/range) | 41/10.7 (39.4/6.9–15.3) |
| Platelet, median, n (range) | 203.0 (30.0–760.0) |
| Creatinine, median (range) | 0.98 (0.5–5.6) |
| Calcium (g/dL), median (range) | 8.7 (6.5–11.1) |
| LDH > 472 IU/L, n/median (%/range) | 20/350.0 (19.2/15.0–1452.0) |
| Albumin (g/L), median (range) | 3.7 (2.4–6.4) |
| Stage, n (%) Durie-Salmon Staging System |
|
| I | 13 (12.5) |
| II | 21 (20.2) |
| III | 70 (67.3) |
| Stage, n (%) International Staging System |
|
| I | 15 (14.4) |
| II | 44 (42.3) |
| III | 45 (43.3) |
| Previous treatment, n (%) | |
| VAD | 37 (35.6) |
| MP | 30 (28.9) |
| Dexamethasone | 29 (27.9) |
| ASCT | 21 (20.2) |
| Thalidomide | 19 (18.3) |
| Others | 21 (20.2) |
VAD: vincristine + Adriamycin + dexamethasone; MP: melphalan + prednisolone; ASCT: autologous stem cell transplantation.